1-2 of 2
Anthony F. Shields
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy

Open Access
Elisabeth Heath, Gregory Dyson, Jennifer R. Ribeiro, Joanne Xiu, Kelsey Poorman, Hirva Mamdani, Mohammed N. Al-Hallak, Anthony F. Shields, Jailan A. Elayoubi, Ira S. Winer, Frank C. Cackowski, Gary A. Puckrein, Gilberto de Lima Lopes, Nathaniel Jones, Ralph J. Hauke, Samuel A. Kareff, Milan Radovich, George W. Sledge, David B. Spetzler, Gregory A. Vidal, John L. Marshall
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (10): 2598–2609.
https://doi.org/10.1158/2767-9764.CRC-24-0321
Published: 04 October 2024
View articletitled, Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy
Open the PDF for Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy in another window
Includes: Supplementary data
Journal Articles

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers

Open Access
Husain Yar Khan, Misako Nagasaka, Yiwei Li, Amro Aboukameel, Md. Hafiz Uddin, Rachel Sexton, Sahar Bannoura, Yousef Mzannar, Mohammed Najeeb Al-Hallak, Steve Kim, Rafic Beydoun, Yosef Landesman, Hirva Mamdani, Dipesh Uprety, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Asfar S. Azmi
Journal: Cancer Research Communications
Cancer Research Communications (2022) 2 (5): 342–352.
https://doi.org/10.1158/2767-9764.CRC-21-0176
Published: 10 May 2022
View articletitled, Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
Open the PDF for Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers in another window
Includes: Supplementary data